Generation of Chimeric ''ABS Nanohemostat'' Complex and Comparing Its Histomorphological In Vivo Effects to the Traditional Ankaferd Hemostat in Controlled Experimental Partial Nephrectomy Model
   
Yazarlar (12)
Emre Huri
Hacettepe Üniversitesi, Türkiye
Yavuz Beyazit
Çanakkale Onsekiz Mart Üniversitesi, Türkiye
Rashad Mammadov
Ihsan Dogramaci Bilkent University, Türkiye
Sıla Toksöz
Ihsan Dogramaci Bilkent University, Türkiye
Ayşe Begüm Tekinay
İhsan Doğramacı Bilkent Üniversitesi, Türkiye
Mustafa O Güler
Ihsan Dogramaci Bilkent University, Türkiye
Hüseyin Üstün
Ankara Numune Training & Research Hospital, Türkiye
Murat Kekilli
Turkiye Yuksek Balsas Training & Res Hosp, Türkiye
Doç. Dr. Mümtaz DADALI Kırşehir Ahi Evran Üniversitesi, Türkiye
Tuğrul Çelik
Fatih University, Türkiye
Hesna Müzeyyen Astarcı
Abant İzzet Baysal Üniversitesi, Türkiye
İbrahim Celalettin Haznedaroğlu
Hacettepe Üniversitesi, Türkiye
Makale Türü Açık Erişim Özgün Makale (SCOPUS dergilerinde yayınlanan tam makale)
Dergi Adı INTERNATIONAL JOURNAL OF BIOMATERIALS
Dergi ISSN 1687-8787 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler PubMed, Scopus, Emerging Sources Citation, IndWeb of Scienceex
Makale Dili İngilizce Basım Tarihi 01-2013
Cilt / Sayı / Sayfa 2013 / 0 / – DOI 10.1155/2013/949460
Makale Linki http://dx.doi.org/10.1155/2013/949460
Özet
Purpose. Using the classical Ankaferd Blood Stopper (ABS) solution to create active hemostasis during partial nephrectomy (PN) may not be so effective due to insufficient contact surface between the ABS hemostatic liquid agent and the bleeding area. In order to broaden the contact surface, we generated a chimeric hemostatic agent, ABS nanohemostat, via combining a self-assembling peptide amphiphile molecule with the traditional Ankaferd hemostat. Materials and Methods. In order to generate ABS nanohemostat, a positively charged Peptide Amphiphile (PA) molecule was synthesized by using solid phase peptide synthesis. For animal experiments, 24 Wistar rats were divided into the following 4 groups: Group 1: control; Group 2: conventional PN with only 0.5 ml Ankaferd hemostat; Group 3: conventional PN with ABS + peptide gel; Group 4: conventional PN with only 0.5 ml peptide solution. Results. Mean warm ischemia times (WITs) were 232.8 +/- 56.3, 65.6 +/- 11.4, 75.5 +/- 17.2, and 58. 1 +/- 17.6 seconds in Group 1 to Group 4, respectively. Fibrosis was not different among the groups, while inflammation was detected to be significantly different in G3 and G4. Conclusions. ABS nanohemostat has comparable hemostatic efficacy to the traditional Ankaferd hemostat in the partial nephrectomy experimental model. Elucidation of the cellular and tissue effects of this chimeric compound may establish a catalytic spark and open new avenues for novel experimental and clinical studies in the battlefield of hemostasis.
Anahtar Kelimeler